Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sangamo Therapeutics
(NQ:
SGMO
)
2.260
-0.040 (-1.74%)
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sangamo Therapeutics
< Previous
1
2
3
4
5
6
7
Next >
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
July 11, 2024
Via
AB Newswire
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
May 15, 2024
Via
Benzinga
SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 09, 2024
SGMO stock results show that Sangamo Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
May 09, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
May 09, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
4 Analysts Assess Sangamo Therapeutics: What You Need To Know
March 13, 2024
Via
Benzinga
Deep Dive Into Sangamo Therapeutics Stock: Analyst Perspectives (4 Ratings)
January 19, 2024
Via
Benzinga
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
May 02, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
April 22, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
March 22, 2024
Via
Benzinga
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
March 22, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Where Sangamo Therapeutics Stands With Analysts
November 06, 2023
Via
Benzinga
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
March 19, 2024
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term...
Via
Benzinga
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
March 13, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
What 8 Analyst Ratings Have To Say About Sangamo Therapeutics
November 06, 2023
Via
Benzinga
Earnings Scheduled For March 13, 2024
March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Via
Benzinga
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
March 12, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
February 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 12, 2024
Via
Benzinga
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
February 12, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
February 06, 2024
Shares of Palantir Technologies Inc. (NYSE: PLTR) rose sharply during today’s pre-market trading after the company reported better-than-expected fourth-quarter sales results and issued guidance.
Via
Benzinga
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
February 05, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 10, 2024
Via
Benzinga
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Exposures
Product Safety
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 15, 2023
Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results.
Via
Benzinga
What To Know About RBC Capital's Downgrade of Sangamo Therapeutics
November 03, 2023
Via
Benzinga
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
November 01, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
November 02, 2023
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.